

### Supplementary table

Tissue	Route of administration	C <sub>max</sub> (nmoles/g)	AUC <sub>INF</sub> (h x nmoles/g)	CL (L/ h)	V <sub>z</sub> (L)	t <sub>1/2</sub> (h)
Plasma	i.v.	378	147	0.021	0.065	2.1
	i.p.	350	225	0.014	0.041	2.1
Liver	i.v.	982	665	0.005	0.004	0.66
	i.p.	596	940	0.003	0.013	2.6
Kidney	i.v.	150	92	0.034	0.26	5.5
	i.p.	212	185	0.017	0.098	4.0
Spleen	i.v.	33	33	0.093	2.8	21
	i.p.	119	108	0.029	1.3	31
Tumour	i.v.	43	117	0.026	1.1	28
	i.p.	27	113	0.027	1.4	35

Table 3: Pharmacokinetic parameters following 100mg/kg i.v. and i.p. injection of 100mg/kg BGC 945 to KB tumour-bearing mice

C<sub>max</sub>, maximum plasma concentration; AUC<sub>INF</sub>, area under the concentration versus time curve extrapolated to infinity; CL, clearance; V<sub>z</sub>, volume of distribution based on the terminal phase; t<sub>1/2</sub>, terminal half life.